Characterization of HIV-1 Reverse Transcriptase Drug Resistance Connection Subdomain Mutation N348I

Characterization of HIV-1 Reverse Transcriptase Drug Resistance Connection Subdomain Mutation N348I

Author: Matthew M. Schuckmann

Publisher:

Published: 2011

Total Pages: 98

ISBN-13:

DOWNLOAD EBOOK

Connection subdomain mutations are a recently discovered class of reverse transcriptase (RT) drug resistance mutations which are positioned at some distance from previously described resistance mutations. The work presented in this thesis investigates drug resistance mechanisms conferred by HIV-1 RT connection subdomain mutation N348I. N348I was chosen as a representative connection subdomain mutation due to its clinical relevance to resistance against drugs belonging to both classes of HIV-1 RT inhibitors: the NRTIs and NNRTIs. N348I is the first, and currently only, clinically relevant HIV-1 RT single amino acid substitution mutation known to confer cross-resistance to drugs from both classes of RT inhibitors. I describe here a mechanism of HIV-1 RT N348I in vitro resistance against inhibition by the NNRTI nevirapine (NVP), where I show the mutant enzyme exhibits a decreased affinity towards inhibitor binding. Using pre-steady state kinetics techniques, I further show in detail how the N348I mutation on either of the heterodimer enzyme's subunits affects enzymatic activities. Interestingly, the mutation on either subunit decreases the rate of catalytic turnover for nucleotide incorporation reactions. The N348I mutant enzyme also displays an altered RNAse H activity, and I demonstrate that the N348I mutation on the p51 subunit provides the major contribution towards this altered activity. I also investigated RT N348I in vitro susceptibility to ddATP, the active form of the NRTI prodrug didanosine (ddI). Multiple mechanisms of NRTI resistance were studied, but significant levels of in vitro resistance to ddATP were not detected despite the fact that the N34I mutant virus has been shown to be resistant to ddI. Here I found that the N348I mutation does not negatively impact the steady-state kinetics of single nucleotide incorporation reactions, or the affinity for nucleotide substrate.


Identification and Characterization of Drug Resistance Mutations in the Reverse Transcriptase of HIV-1 Crf08_bc Subtype

Identification and Characterization of Drug Resistance Mutations in the Reverse Transcriptase of HIV-1 Crf08_bc Subtype

Author: Xiaomin Zhang

Publisher: Open Dissertation Press

Published: 2017-01-27

Total Pages:

ISBN-13: 9781361383315

DOWNLOAD EBOOK

This dissertation, "Identification and Characterization of Drug Resistance Mutations in the Reverse Transcriptase of HIV-1 CRF08_BC Subtype" by Xiaomin, Zhang, 张晓敏, was obtained from The University of Hong Kong (Pokfulam, Hong Kong) and is being sold pursuant to Creative Commons: Attribution 3.0 Hong Kong License. The content of this dissertation has not been altered in any way. We have altered the formatting in order to facilitate the ease of printing and reading of the dissertation. All rights not granted by the above license are retained by the author. Abstract: The emergence of drug resistant virus variants containing one or more mutations has become one of the major reasons causing long-term treatment failure and leads to rapid progress into the acquired immunodeficiency syndrome (AIDS). Polymorphisms among different subtypes can affect the magnitude of drug resistance and the propensity to acquire certain resistance mutations. Most previous studies have focused on HIV-1 subtype B. Therefore, identification and characterization of the novel mutations in non-B subtype are necessary for developing novel efficient antiviral agents and optimizing therapies for the patients in the non-B subtype prevalent regions. HIV-1 CRF08_BC is one of the major predominant subtypes in China, but studies of the drug resistance mutations in this subtype are limited so that the relative information is still poor. Previously, we selected some novel mutations in the viral reverse transcriptase (RT) presenting as accumulated patterns in a clinical isolate 2007CNGX-HK of CRF08_BC subtype during in vitro cultures with increasing concentration of NVP, one of the mostly used NNRTIs in the first-line therapy for HIV-1 infection. The purpose of this study is to further characterize these novel mutations either alone or in combination with the other reported mutations. We first constructed a wild type replication-competent infectious clone pBRGX from the isolated virus 2007CNGX-HK and confirmed CCR5 was the co-receptor for HIV-1 CRF08_BC subtype virus infection. Besides, we also found that a low-copy number vector might be better to construct a large molecular clone (>10k) than a high-copy number vector, and parental long terminal repeats (LTRs) were supposed to play a vital role in HIV-1 replication. Based on pBRGX, novel mutations were induced either alone or together with other reported mutations by site-mutagenesis. Twenty-one virus variants were obtained from transfection and used for phenotypic assays, replication capacity and RT activity tests. Results showed that: 1) D404N in the connection subdomain of RT was firstly demonstrated to be a novel resistance-related mutation to non-nucleoside reverse transcriptase inhibitors (NNRTIs), which also resulted in great loss of replication capacity (RC). Modeling study suggested that the mutation D404N might abolish the hydrogen bonds between residue 404 and K30 in p51 or K431 in p66, leading to impaired RT subunit structure and resulting in drug resistance and reduced RC. 2) L228I, A139V and Y232H were new accessory drug resistance mutations to NNRTIs at cost of RC loss. 3) C162Y enhanced the drug resistance level of E138R to NNRTIs but not impair viral RC. 4) Reported mutations E138G/K/R, Y181C, Y188C and H221Y in subtype B were also critical for viral susceptibility to NNRTIs in subtype CRF08_BC. In conclusion, our data indicate that novel mutations may play an active role in the regulation of NNRTI resistance in non-B subtype, reinforcing the complexity of RT inhibitor resistance. Several reported drug-resistance mutations in B subtype also exhibited similar effects in CRF08_BC subtype. These mutations might be considered for predicting clinical response to antiretroviral therapy and for assessing the efficacies of new drugs. Further clinical studies are necessary to demonstrate the clinical significance of these novel mutations. Subjects: Reve


From the Notorious to the Novel

From the Notorious to the Novel

Author: Mia Biondi

Publisher:

Published: 2013

Total Pages:

ISBN-13:

DOWNLOAD EBOOK

"34 million individuals worldwide are currently infected with the human immunodeficiency virus (HIV). Following the isolation of HIV, the first direct acting antiviral was approved. This particular compound targeted the reverse transcriptase (RT) enzyme, and resulted in a decrease in viral load in patients receiving therapy. Shortly after, it was demonstrated that the use of a single inhibitor quickly leads to the selection of drug resistance mutations, and subsequently to viral rebound. To combat this, combination therapy was introduced which targets multiple proteins, including RT and other enzymes, such as HIV integrase (IN). RT reverse transcribes the single-stranded RNA genome into double-stranded DNA, followed by the insertion of this product into the host genome by IN. A detailed understanding of the mechanism of action of the drug target, the inhibitor itself, as well as how resistance-associated mutations act, is necessary to improve current therapies. Typically, drug resistance mutations occur near the binding site of the inhibitor. However, the first part of this thesis examines a mutation in HIV-1 RT, N348I, which confers, and is distant from the binding site of, both nucleoside reverse transcriptase inhibitors, and non-nucleoside reverse transcriptase inhibitors (NNRTIs). We describe the specific stage during HIV-1 reverse transcription where N348I exerts its effect on the first-generation NNRTI, neverapine, but not efavirenz. RT is targeted by multiple classes of drugs, while only one inhibitor, raltegravir (RAL), is currently approved to target HIV-1 IN. The development of IN inhibitors has been hindered by the lack of structural information with respect to the enzyme, IN-DNA interactions, as well as the mechanism of action of RAL. We pinpoint several interactions between HIV-1 IN and its DNA substrate, which are important for enzymatic activity. We also elucidate the contributions of these interactions in the context of inhibition by RAL, with respect to the wild-type enzyme, as well as the IN drug resistance mutation N155H. Following the acquisition of primary resistance mutations in HIV-1 IN, such as N155H, secondary mutations often appear. These mutations compensate for decreased viral fitness, and can potentially amplify resistance. The final study presented herein, examines whether one such mutation recently identified in RAL-experienced patients at position N117, confers resistance to RAL." --


Antimicrobial Drug Resistance

Antimicrobial Drug Resistance

Author: Douglas L. Mayers

Publisher: Springer

Published: 2017-06-19

Total Pages: 759

ISBN-13: 3319467182

DOWNLOAD EBOOK

The two volumes included in Antimicrobial Drug Resistance, Second Edition is an updated, comprehensive and multidisciplinary reference covering the area of antimicrobial drug resistance in bacteria, fungi, viruses, and parasites from basic science, clinical, and epidemiological perspectives. This newly revised compendium reviews the most current research and development on drug resistance while still providing the information in the accessible format of the first edition. The first volume, Antimicrobial Drug Resistance: Mechanisms of Drug Resistance, is dedicated to the biological basis of drug resistance and effective avenues for drug development. With the emergence of more drug-resistant organisms, the approach to dealing with the drug resistance problem must include the research of different aspects of the mechanisms of bacterial resistance and the dissemination of resistance genes as well as research utilizing new genomic information. These approaches will permit the design of novel strategies to develop new antibiotics and preserve the effectiveness of those currently available. The second volume, Antimicrobial Drug Resistance: Clinical and Epidemiological Aspects, is devoted to the clinical aspects of drug resistance. Although there is evidence that restricted use of a specific antibiotic can be followed by a decrease in drug resistance to that agent, drug resistance control is not easily achieved. Thus, the infectious diseases physician requires input from the clinical microbiologist, antimicrobial stewardship personnel, and infection control specialist to make informed choices for the effective management of various strains of drug-resistant pathogens in individual patients. This 2-volume set is an important reference for students in microbiology, infectious diseases physicians, medical students, basic scientists, drug development researchers, microbiologists, epidemiologists, and public health practitioners.


HIV/AIDS: New Insights for the Healthcare Professional: 2012 Edition

HIV/AIDS: New Insights for the Healthcare Professional: 2012 Edition

Author:

Publisher: ScholarlyEditions

Published: 2012-12-10

Total Pages: 1894

ISBN-13: 146496971X

DOWNLOAD EBOOK

HIV/AIDS: New Insights for the Healthcare Professional / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about HIV/AIDS. The editors have built HIV/AIDS: New Insights for the Healthcare Professional / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about HIV/AIDS in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of HIV/AIDS: New Insights for the Healthcare Professional / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.


Virus Diseases: New Insights for the Healthcare Professional: 2011 Edition

Virus Diseases: New Insights for the Healthcare Professional: 2011 Edition

Author:

Publisher: ScholarlyEditions

Published: 2012-01-09

Total Pages: 708

ISBN-13: 1464900116

DOWNLOAD EBOOK

Virus Diseases: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Virus Diseases. The editors have built Virus Diseases: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Virus Diseases in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Virus Diseases: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.


Kucers' The Use of Antibiotics

Kucers' The Use of Antibiotics

Author: M. Lindsay Grayson

Publisher: CRC Press

Published: 2017-10-02

Total Pages: 5390

ISBN-13: 1000031497

DOWNLOAD EBOOK

Kucers’ The Use of Antibiotics is the definitive, internationally-authored reference, providing everything that the infectious diseases specialist and prescriber needs to know about antimicrobials in this vast and rapidly developing field. The much-expanded Seventh Edition comprises 4800 pages in 3 volumes in order to cover all new and existing therapies, and emerging drugs not yet fully licensed. Concentrating on the treatment of infectious diseases, the content is divided into four sections - antibiotics, anti-fungal drugs, anti-parasitic drugs, and anti-viral drugs - and is highly structured for ease of reference. Each chapter is organized in a consistent format, covering susceptibility, formulations and dosing (adult and pediatric), pharmacokinetics and pharmacodynamics, toxicity, and drug distribution, with detailed discussion regarding clinical uses - a feature unique to this title. Compiled by an expanded team of internationally renowned and respected editors, with expert contributors representing Europe, Africa, Asia, Australia, South America, the US, and Canada, the Seventh Edition adopts a truly global approach. It remains invaluable for anyone using antimicrobial agents in their clinical practice and provides, in a systematic and concise manner, all the information required when prescribing an antimicrobial to treat infection.


Viral Polymerases

Viral Polymerases

Author: Satya Prakash Gupta

Publisher: Academic Press

Published: 2018-10-29

Total Pages: 498

ISBN-13: 0128154233

DOWNLOAD EBOOK

Viral Polymerases: Structures, Functions and Roles as Antiviral Drug Targets presents in-depth study information on the structure and functions of polymerases and their roles in the lifecycle of viruses, and as drug targets. Viral polymerases constitute a vital component in the lifecycle of many viruses, such as human immunodeficiency virus (HIV), hepatitis viruses, influenza virus, and several others. They are essentially required for the replication of viruses. Thus, the polymerases that can be found in viruses (called viral polymerases) represent favorable targets for the design and development of antiviral drugs. Provides comprehensive, state-of-the-art coverage on virus infections, the virus lifecycle, and mechanisms of polymerase inhibition Analyzes the structure-activity relationships of inhibitors of each viral polymerase Presents a consistent and comprehensive coverage of all aspects of viral polymerases, including structure, function and their role as antiviral drug targets